Global Beta-lactam and Beta-lactamase Inhibitors Market Size, Share, Trends and Forecast 2022-2030

Description

Market Analysis and Insights: Global Beta-lactam and Beta-lactamase Inhibitors Market
β-Lactams are the most widely used class of antibiotics. Since the discovery of benzylpenicillin in the 1920s, thousands of new penicillin derivatives and related β-lactam classes of cephalosporins, cephamycins, monobactams, and carbapenems have been discovered. Each new class of b-lactam has been developed either to increase the spectrum of activity to include additional bacterial species or to address specific resistance mechanisms that have arisen in the targeted bacterial population. Resistance to β-lactams is primarily because of bacterially produced β-lactamase enzymes that hydrolyze the β-lactam ring, thereby inactivating the drug. The newest effort to circumvent resistance is the development of novel broad-spectrum β-lactamase inhibitors that work against many problematic β-lactamases, including cephalosporinases and serine-based carbapenemases, which severely limit therapeutic options.

Due to the COVID-19 pandemic, the global Beta-lactam and Beta-lactamase Inhibitors market size is estimated to be worth US$ 28910 million in 2022 and is forecast to a readjusted size of US$ 32370 million by 2028 with a CAGR of 1.9% during the review period. Fully considering the economic change by this health crisis, Penicillins accounting for % of the Beta-lactam and Beta-lactamase Inhibitors global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While Oral segment is altered to an % CAGR throughout this forecast period.

In the global market, the core manufacturers of Beta-lactam and Beta-lactamase Inhibitors include Pfizer and Novartis (Sandoz) etc, and the top 2 manufacturers account for about 10% of the market share. The market include Asia Pacific, Europe and North America, with a share of 33%, 32% and 28%. cephalosporins accounted for 28% and penicillins accounted for 17%. The product is mainly used in intravenous and oral, with a share of 65% and 35%.

Market Segments

The authors of this research report have explored the key segments: Type and Application. The report offers an in-depth breakdown of type and application segments and their sub-segments. The lucrativeness and growth potential have been looked into by the industry experts in this report. This section of the report also provides sales and revenue forecast data by type and application segments based on sales, price, and revenue for the period 2017-2028. The specialists, to broaden the understanding of the users, have done value chain and raw material analysis in this section.

Segment by Type

Penicillins

Cephalosporins

Carbapenems

Monobactams

Combinations

Segment by Application

Oral

Intravenous

Consequence of Covid-19 Pandemic

The authors of this study have enlightened the readers on the rise and effect of the Covid-19 outbreak on the development. They have investigated the changes brought about in the demand/supply side, consumption, supply chain, and sales/manufacturing. The readers will get familiar with the measures that have helped the key players to bring the Beta-lactam and Beta-lactamase Inhibitors market back to the pre-covid levels.

Trends & Prospects

In this segment of the report, the specialists have delved into the key growth opportunities that are likely to emerge. This will aid the key players to simplify complex issues related to business and frame future strategies to compete in this competitive environment. This section will certainly assist the players to boldly position their business.

By Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Russia

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Indonesia

Thailand

Malaysia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Competitive Outlook

In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and share analysis of the prominent players are also provided in this section. They have also provided reliable sales and revenue data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:

Pfizer

Novartis (Sandoz)

TEVA

Merck

AbbVie (Allergan)

Sumitomo Dainippon

Hikma

Aurobindo Pharma

Wockhardt

Lupin Limited

Fresenius Kabi

B. Braun

USantibiotics

Qilu Pharmaceutical

ACS Dobfar

Nichi-Iko (Sagent)

Antibiotice

TABLE OF CONTENT

1 Study Coverage
1.1 Beta-lactam and Beta-lactamase Inhibitors Product Introduction

1.2 Market by Type

1.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Type, 2017 VS 2021 VS 2028

1.2.2 Penicillins

1.2.3 Cephalosporins

1.2.4 Carbapenems

1.2.5 Monobactams

1.2.6 Combinations

1.3 Market by Application

1.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Market Size Growth Rate by Application, 2017 VS 2021 VS 2028

1.3.2 Oral

1.3.3 Intravenous

1.4 Study Objectives

1.5 Years Considered

2 Executive Summary

2.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales Estimates and Forecasts 2017-2028

2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Estimates and Forecasts 2017-2028

2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region: 2017 VS 2021 VS 2028

2.4 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region

2.4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2022)

2.4.2 Global Sales Beta-lactam and Beta-lactamase Inhibitors by Region (2023-2028)

2.5 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region

2.5.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2022)

2.5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2023-2028)

2.6 North America

2.7 Europe

2.8 Asia-Pacific

2.9 Latin America

2.10 Middle East & Africa

3 Competition by Manufacturers

3.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Manufacturers

3.1.1 Global Top Beta-lactam and Beta-lactamase Inhibitors Manufacturers by Sales (2017-2022)

3.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Manufacturers (2017-2022)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Beta-lactam and Beta-lactamase Inhibitors in 2021

3.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers

3.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Manufacturers (2017-2022)

3.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Manufacturers (2017-2022)

3.2.3 Global Top 10 and Top 5 Companies by Beta-lactam and Beta-lactamase Inhibitors Revenue in 2021

3.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Price by Manufacturers (2017-2022)

3.4 Analysis of Competitive Landscape

3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Beta-lactam and Beta-lactamase Inhibitors Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.4.3 Global Beta-lactam and Beta-lactamase Inhibitors Manufacturers Geographical Distribution

3.5 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Type

4.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Type (2017-2022)

4.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Type (2023-2028)

4.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Type (2017-2028)

4.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Type

4.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Type (2017-2022)

4.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Type (2023-2028)

4.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Type (2017-2028)

4.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type

4.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Type (2017-2022)

4.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Type (2023-2028)

5 Market Size by Application

5.1 Global Beta-lactam and Beta-lactamase Inhibitors Sales by Application

5.1.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Sales by Application (2017-2022)

5.1.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Sales by Application (2023-2028)

5.1.3 Global Beta-lactam and Beta-lactamase Inhibitors Sales Market Share by Application (2017-2028)

5.2 Global Beta-lactam and Beta-lactamase Inhibitors Revenue by Application

5.2.1 Global Beta-lactam and Beta-lactamase Inhibitors Historical Revenue by Application (2017-2022)

5.2.2 Global Beta-lactam and Beta-lactamase Inhibitors Forecasted Revenue by Application (2023-2028)

5.2.3 Global Beta-lactam and Beta-lactamase Inhibitors Revenue Market Share by Application (2017-2028)

5.3 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application

5.3.1 Global Beta-lactam and Beta-lactamase Inhibitors Price by Application (2017-2022)

5.3.2 Global Beta-lactam and Beta-lactamase Inhibitors Price Forecast by Application (2023-2028)

6 North America

6.1 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type

6.1.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028)

6.1.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028)

6.2 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

6.2.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028)

6.2.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028)

6.3 North America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country

6.3.1 North America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028)

6.3.2 North America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028)

6.3.3 United States

6.3.4 Canada

7 Europe

7.1 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Type

7.1.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028)

7.1.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028)

7.2 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

7.2.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028)

7.2.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028)

7.3 Europe Beta-lactam and Beta-lactamase Inhibitors Market Size by Country

7.3.1 Europe Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028)

7.3.2 Europe Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028)

7.3.3 Germany

7.3.4 France

7.3.5 U.K.

7.3.6 Italy

7.3.7 Russia

8 Asia Pacific

8.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Type

8.1.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028)

8.1.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028)

8.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

8.2.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028)

8.2.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028)

8.3 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Market Size by Region

8.3.1 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Sales by Region (2017-2028)

8.3.2 Asia Pacific Beta-lactam and Beta-lactamase Inhibitors Revenue by Region (2017-2028)

8.3.3 China

8.3.4 Japan

8.3.5 South Korea

8.3.6 India

8.3.7 Australia

8.3.8 China Taiwan

8.3.9 Indonesia

8.3.10 Thailand

8.3.11 Malaysia

9 Latin America

9.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Type

9.1.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028)

9.1.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028)

9.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

9.2.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028)

9.2.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028)

9.3 Latin America Beta-lactam and Beta-lactamase Inhibitors Market Size by Country

9.3.1 Latin America Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028)

9.3.2 Latin America Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028)

9.3.3 Mexico

9.3.4 Brazil

9.3.5 Argentina

10 Middle East and Africa

10.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Type

10.1.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Type (2017-2028)

10.1.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Type (2017-2028)

10.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Application

10.2.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Application (2017-2028)

10.2.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Application (2017-2028)

10.3 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Market Size by Country

10.3.1 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Sales by Country (2017-2028)

10.3.2 Middle East and Africa Beta-lactam and Beta-lactamase Inhibitors Revenue by Country (2017-2028)

10.3.3 Turkey

10.3.4 Saudi Arabia

11 Company Profiles

11.1 Pfizer

11.1.1 Pfizer Corporation Information

11.1.2 Pfizer Overview

11.1.3 Pfizer Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.1.4 Pfizer Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 Pfizer Recent Developments

11.2 Novartis (Sandoz)

11.2.1 Novartis (Sandoz) Corporation Information

11.2.2 Novartis (Sandoz) Overview

11.2.3 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.2.4 Novartis (Sandoz) Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 Novartis (Sandoz) Recent Developments

11.3 TEVA

11.3.1 TEVA Corporation Information

11.3.2 TEVA Overview

11.3.3 TEVA Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.3.4 TEVA Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.3.5 TEVA Recent Developments

11.4 Merck

11.4.1 Merck Corporation Information

11.4.2 Merck Overview

11.4.3 Merck Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.4.4 Merck Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.4.5 Merck Recent Developments

11.5 AbbVie (Allergan)

11.5.1 AbbVie (Allergan) Corporation Information

11.5.2 AbbVie (Allergan) Overview

11.5.3 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.5.4 AbbVie (Allergan) Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.5.5 AbbVie (Allergan) Recent Developments

11.6 Sumitomo Dainippon

11.6.1 Sumitomo Dainippon Corporation Information

11.6.2 Sumitomo Dainippon Overview

11.6.3 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.6.4 Sumitomo Dainippon Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.6.5 Sumitomo Dainippon Recent Developments

11.7 Hikma

11.7.1 Hikma Corporation Information

11.7.2 Hikma Overview

11.7.3 Hikma Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.7.4 Hikma Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.7.5 Hikma Recent Developments

11.8 Aurobindo Pharma

11.8.1 Aurobindo Pharma Corporation Information

11.8.2 Aurobindo Pharma Overview

11.8.3 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.8.4 Aurobindo Pharma Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.8.5 Aurobindo Pharma Recent Developments

11.9 Wockhardt

11.9.1 Wockhardt Corporation Information

11.9.2 Wockhardt Overview

11.9.3 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.9.4 Wockhardt Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.9.5 Wockhardt Recent Developments

11.10 Lupin Limited

11.10.1 Lupin Limited Corporation Information

11.10.2 Lupin Limited Overview

11.10.3 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.10.4 Lupin Limited Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.10.5 Lupin Limited Recent Developments

11.11 Fresenius Kabi

11.11.1 Fresenius Kabi Corporation Information

11.11.2 Fresenius Kabi Overview

11.11.3 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.11.4 Fresenius Kabi Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.11.5 Fresenius Kabi Recent Developments

11.12 B. Braun

11.12.1 B. Braun Corporation Information

11.12.2 B. Braun Overview

11.12.3 B. Braun Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.12.4 B. Braun Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.12.5 B. Braun Recent Developments

11.13 USantibiotics

11.13.1 USantibiotics Corporation Information

11.13.2 USantibiotics Overview

11.13.3 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.13.4 USantibiotics Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.13.5 USantibiotics Recent Developments

11.14 Qilu Pharmaceutical

11.14.1 Qilu Pharmaceutical Corporation Information

11.14.2 Qilu Pharmaceutical Overview

11.14.3 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.14.4 Qilu Pharmaceutical Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.14.5 Qilu Pharmaceutical Recent Developments

11.15 ACS Dobfar

11.15.1 ACS Dobfar Corporation Information

11.15.2 ACS Dobfar Overview

11.15.3 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.15.4 ACS Dobfar Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.15.5 ACS Dobfar Recent Developments

11.16 Nichi-Iko (Sagent)

11.16.1 Nichi-Iko (Sagent) Corporation Information

11.16.2 Nichi-Iko (Sagent) Overview

11.16.3 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.16.4 Nichi-Iko (Sagent) Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.16.5 Nichi-Iko (Sagent) Recent Developments

11.17 Antibiotice

11.17.1 Antibiotice Corporation Information

11.17.2 Antibiotice Overview

11.17.3 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Sales, Price, Revenue and Gross Margin (2017-2022)

11.17.4 Antibiotice Beta-lactam and Beta-lactamase Inhibitors Product Model Numbers, Pictures, Descriptions and Specifications

11.17.5 Antibiotice Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Beta-lactam and Beta-lactamase Inhibitors Industry Chain Analysis

12.2 Beta-lactam and Beta-lactamase Inhibitors Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Beta-lactam and Beta-lactamase Inhibitors Production Mode & Process

12.4 Beta-lactam and Beta-lactamase Inhibitors Sales and Marketing

12.4.1 Beta-lactam and Beta-lactamase Inhibitors Sales Channels

12.4.2 Beta-lactam and Beta-lactamase Inhibitors Distributors

12.5 Beta-lactam and Beta-lactamase Inhibitors Customers

13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis

13.1 Beta-lactam and Beta-lactamase Inhibitors Industry Trends

13.2 Beta-lactam and Beta-lactamase Inhibitors Market Drivers

13.3 Beta-lactam and Beta-lactamase Inhibitors Market Challenges

13.4 Beta-lactam and Beta-lactamase Inhibitors Market Restraints

14 Key Findings in The Global Beta-lactam and Beta-lactamase Inhibitors Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

Choose License Type

Checkout Inquiry Sample